KalGene Pharmaceuticals closes Series A financing to support Alzheimer’s drug program

November 27, 2017

KalGene Pharmaceuticals announced today the closing of a Series A financing for their Alzheimer’s drug program and to support the development of their lead therapeutic compound. The Institute supports KalGene through a collaborative project with Dr. Rosa Neto of McGill University, funded through the Early Phase Clinical Trials 2015 program.

The investment was led by Lumira Capital, and supported by Accel-Rx and others.

Read about Dr. Rosa Neto’s Institute-funded work.

Read the full press release here.